This Article Full Text Full Text (PDF) All Versions of this Article: 91/8/2871    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barinas-Mitchell, E. Articles by Pietropaolo, M. Search for Related Content PubMed PubMed Citation Articles by Barinas-Mitchell, E. Articles by Pietropaolo, M. Related Collections Diabetes and Insulin

The Prevalence of the 65-Kilodalton Isoform of Glutamic Acid Decarboxylase Autoantibodies by Glucose Tolerance Status in Elderly Patients from the Cardiovascular Health Study

Department of Epidemiology (E.B.-M., L.H.K., M.P.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261; and Division of Immunogenetics (S.P., Y.-J.Z., T.H., M.P.), Diabetes Institute, Department of Pediatrics, Rangos Research Center, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213

Address all correspondence and requests for reprints to: Emma Barinas-Mitchell, Ph.D., Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 130 DeSoto Street, Pittsburgh, Pennsylvania 15261. E-mail: barinas{at}edc.pitt.edu.

Context: Autoantibodies (AA) to glutamic acid decarboxylase (GAD65), a determinant of risk for autoimmune diabetes, have been found in up to 10% of patients with type 2 diabetes. In older adults, this marker may also serve as a determinant of risk for autoimmune diabetes and enhance diabetes classification.

Objective: The objective of this study was to evaluate the relationship between GAD65AA and glucose tolerance status, current diabetes treatment, and clinical measures in older adults.

Design: GAD65AA were measured at baseline in 3318 participants from the Cardiovascular Health Study, a cohort study of 5888 individuals 65 or older.

Setting: The population-based cohort was recruited from four U.S. sites.

Patients: Patients included all Cardiovascular Health Study participants with known diabetes, newly diagnosed diabetes, impaired fasting glucose, impaired glucose tolerance, and a sample of normal glucose-tolerant participants.

Main Outcome Measures: GAD65AA, body mass index, fasting glucose and insulin levels, blood pressure, lipid levels, and diabetes treatment at baseline were measured.

Results: The prevalence of GAD65AA increased with decreasing glucose tolerance in both Blacks (n = 560) and Whites (n = 2730), being more pronounced in known diabetic individuals. GAD65AA were found in 2.3, 5.8, 7.8, and 8.3% of diabetic participants, reporting use of no diabetes medication, oral hypoglycemic agents, insulin only, and both oral hypoglycemic agents and insulin, respectively (P = 0.02, linear trend). Among diabetic participants, GAD65AA positivity was associated with diabetes treatment, higher fasting glucose, and lower body mass index.

Conclusions: Even among older individuals with diabetes, GAD65AA may be a useful marker in identifying a subgroup of autoimmune diabetes, serve as a marker of insulin requirement, and remain stable over years.

This article has been cited by other articles:

				M. Pietropaolo, E. Barinas-Mitchell, and L. H. Kuller The Heterogeneity of Diabetes: Unraveling a Dispute: Is Systemic Inflammation Related to Islet Autoimmunity? Diabetes, May 1, 2007; 56(5): 1189 - 1197. [Abstract] [Full Text] [PDF]